Altimmune Shares Sink This Year, But Retail Traders See A Buyout On The Horizon A Betaville report suggested Altimmune has begun a strategic review with an adviser, with speculation that three major pharmaceutical firms may be involved.
Altimmune Expands Weight-Loss Drug Pemvidutide's Potential To Alcohol-Related Disorders Altimmune plans Phase 2 trials in 2025 for pemvidutide in alcohol use disorder and liver disease, highlighting weight loss and liver health benefits.
ALT Stock Earnings: Altimmune Misses EPS for Q2 2024 ALT stock results show that Altimmune missed analyst estimates for earnings per share the second quarter of 2024.
Mastering Market Chaos: StoryTrading’s Top 5 Stocks You Can’t Ignore The trading landscape is alive with opportunity, shaped by a mix of macroeconomic events and sector-specific moves.
MarketBeat Week in Review – 11/4 - 11/8 Markets rallied strongly this week on clarity about the election and an expected rate cut, but next week's inflation readings will determine if momentum lasts
How Altimmune Could Grab a Big Chunk of the GLP-1 Market Altimmune is working on a developmental weight loss drug that could have strong benefits for an important segment of GLP-1 users.
Novo Nordisk, Eli Lilly Could Face Downward Pressure Despite Market Dominance From Potentially 16 New Obesity Drugs: See The Names The $200B GLP-1 market is set to expand with 16 new obesity drugs launching by 2029, challenging Novo Nordisk and Eli Lilly's dominance while addressing scalability and pricing concerns.
3 Promising Biotech Stocks for the Long-Term: August 2024 Some of the best biotech opportunities can be found in oversold obesity treatment stocks. Here are just a few.
The 7 Best Under $10 Stocks to Buy in August 2024 Buying low-priced stocks carries risk, but lower interest rates may lower the risk premium on these best stocks under $10.
Prediction: This Weight Loss Stock Will Be Acquired Within the Next Year Altimmune is a little-known pharmaceutical company looking to disrupt the weight loss space.
